Medications

FDA investigates deaths of patients on antipsychotic drug

(HealthDay)—Following the deaths of two patients three to four days after receiving a dose of Zyprexa Relprevv (olanzapine pamoate) via intramuscular injection, the U.S. Food and Drug Administration is conducting an investigation ...

Psychology & Psychiatry

Antipsychotic meds not that helpful for depression, study finds

(HealthDay)—For people who don't fully respond to antidepressants, adding commonly prescribed antipsychotic drugs appears to be only slightly effective and is linked to unwelcome side effects, a new study finds.

Psychology & Psychiatry

Use of adjunctive antipsychotic medications in depression

A study published this week in PLOS Medicine finds that while antipsychotic medications are associated with small-to-moderate improvements in depressive symptoms in adults, there is little evidence for improvement on measures ...

Psychology & Psychiatry

Antipsychotics accelerate patient sedation, study finds

(Medical Xpress)—A new study is shedding light on the use of sedative drugs in hospitals and has proven certain clinically used drug combinations to be faster and more effective in sedating highly aggressive patients in ...

Oncology & Cancer

ASCO: For chemo's nausea, olanzapine beats metoclopramide

(HealthDay) -- For patients receiving highly emetogenic chemotherapy who experience breakthrough chemotherapy-induced nausea and vomiting, treatment with olanzapine (Zyprexa) is significantly better than treatment with metoclopramide, ...

page 1 from 2

Olanzapine

Olanzapine (trade names Zyprexa, Zalasta, Zolafren, Olzapin, Oferta, Zypadhera or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder. Olanzapine is structurally similar to clozapine, but is classified as a thienobenzodiazepine. The olanzapine formulations are manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper expires in 2011 (in October 2009 a Canadian judge ruled that the 1991 patent was invalid). Sales of Zyprexa in 2008 were $2.2B in the US alone, and $4.7B in total.

This text uses material from Wikipedia, licensed under CC BY-SA